Research is ongoing to explore the potential of osimertinib beyond its current indications. Studies are investigating its use in earlier stages of NSCLC, as an adjuvant therapy post-surgery, and in combination with other treatments such as immunotherapy. These efforts aim to expand the therapeutic benefits of osimertinib and improve outcomes for a broader range of cancer patients.
